NasdaqGS:RXRXBiotechs
Early Safety Data And FDA Signals Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX)
In early June 2026, Recursion Pharmaceuticals presented at the Goldman Sachs 47th Annual Global Healthcare Conference and highlighted progress in its AI-enabled drug discovery platform alongside clinical updates for REC-1245 and REC-4881.
A key insight is that initial safety signals for REC-1245 in the DHALIA solid-tumor trial and anticipated FDA feedback on REC-4881’s regulatory path are sharpening investor focus on how Recursion’s AI tools may translate into tangible clinical and...